Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
65 hedge funds and large institutions have $62M invested in Adamas Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 21 increasing their positions, 17 reducing their positions, and 9 closing their positions.
24% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 17
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
17% more capital invested
Capital invested by funds: $52.9M → $62M (+$9.09M)
3% more funds holding
Funds holding: 63 → 65 (+2)
45% less call options, than puts
Call options by funds: $61K | Put options by funds: $111K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.46M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.36M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$730K |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$646K |
| 5 |
JGC
J. Goldman & Co
New York
|
+$417K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$2.65M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$2.27M |
| 3 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$1.27M |
| 4 |
DAM
Deltec Asset Management
New York
|
-$473K |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
-$220K |
ADMS Hedge Fund Activity: Q4 2020 in Review
65 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q4 2020, worth a combined $62M — up 17% from $52.9M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ADMS positions and 9 closed out — a net gain of 2 holders — while 21 added to existing stakes and 17 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $3.46M. The largest seller was Emerald Advisers, exiting entirely with an estimated $2.65M sold.
- 65 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q4 2020, up from 63 in Q3 2020.
- Funds reported $62M of Adamas Pharmaceuticals stock for Q4 2020, up 17% quarter-over-quarter.
- 11 funds opened new Adamas Pharmaceuticals positions in Q4 2020 and 9 closed out, a net change of +2 holders.
- The largest Adamas Pharmaceuticals buyer in Q4 2020 was Morgan Stanley, an estimated $3.46M added.
- The largest Adamas Pharmaceuticals seller in Q4 2020 was Emerald Advisers, an estimated $2.65M sold.
Based on aggregated 13F filings for Q4 2020.